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Identification of novel molecular 
signatures of IgA nephropathy 
through an integrative -omics 
analysis
Magdalena Krochmal1,2, Katryna Cisek3, Szymon Filip1, Katerina Markoska8, Clare Orange7, 
Jerome Zoidakis1, Chara Gakiopoulou9, Goce Spasovski8, Harald Mischak3,5, Christian Delles  6, 
Antonia Vlahou1 & Joachim Jankowski2,4
IgA nephropathy (IgAN) is the most prevalent among primary glomerular diseases worldwide. Although 
our understanding of IgAN has advanced significantly, its underlying biology and potential drug targets 
are still unexplored. We investigated a combinatorial approach for the analysis of IgAN-relevant 
-omics data, aiming at identification of novel molecular signatures of the disease. Nine published 
urinary proteomics datasets were collected and the reported differentially expressed proteins in IgAN 
vs. healthy controls were integrated into known biological pathways. Proteins participating in these 
pathways were subjected to multi-step assessment, including investigation of IgAN transcriptomics 
datasets (Nephroseq database), their reported protein-protein interactions (STRING database), kidney 
tissue expression (Human Protein Atlas) and literature mining. Through this process, from an initial 
dataset of 232 proteins significantly associated with IgAN, 20 pathways were predicted, yielding 657 
proteins for further analysis. Step-wise evaluation highlighted 20 proteins of possibly high relevance to 
IgAN and/or kidney disease. Experimental validation of 3 predicted relevant proteins, adenylyl cyclase-
associated protein 1 (CAP1), SHC-transforming protein 1 (SHC1) and prolylcarboxypeptidase (PRCP) 
was performed by immunostaining of human kidney sections. Collectively, this study presents an 
integrative procedure for -omics data exploitation, giving rise to biologically relevant results.
IgA nephropathy (IgAN) is the most common form of primary glomerular disease worldwide, progressing 
to renal failure in almost one third of cases1, 2. IgAN is characterized by the presence of mesangial deposits of 
IgA-containing immune complexes. Clinical manifestation of the disease is highly variable with symptoms rang-
ing from microscopic to severe proteinuria, haematuria and histopathological lesions that might include mild 
mesangial thickening to membranoproliferative glomerulonephritis3. Moreover, IgAN prevalence depends on 
ethnicity, with highest in Asians and lowest amongst African-Americans4 and has unequal gender distribution, 
affecting males more frequently than females (male-to-female ratio of 3:1 in Europeans)5. Currently, renal biopsy 
remains the gold standard of diagnosis of IgAN; however, due to its invasive nature, it is routinely not performed 
at often asymptomatic, early stages or for serial monitoring of disease progression6, 7.
The pathogenesis of IgAN currently remains only partially understood, despite numerous studies that helped 
in elucidation of several molecular mechanisms involved in the disease. These collectively resulted in the devel-
opment of the IgAN autoimmune pathogenesis model, proposing disease development in a four-hit manner: (1) 
overproduction of aberrantly glycosylated IgA1; (2) production of glycan-specific IgG and IgA autoantibodies 
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recognizing the undergalactosylated IgA1 molecule; (3) triggering the formation of immune complexes; (4) and 
their accumulation in the glomerular mesangium, which initiates renal injury through mesangial cells and com-
plement activation8, 9. Nevertheless, many questions stay unanswered, such as the cause of preferential deposition 
of immune complexes in mesangium and its connection with proteinuria and haematuria.
According to clinical practice guidelines for IgAN treatment10, proteinuria is considered the strongest prog-
nostic factor in IgAN. Recommended treatment options aim at slowing the disease progression and are limited 
to blood pressure control or non-specific immunosuppression with corticosteroids or other immunosuppressive 
agents11, 12. Currently, disease-specific therapy does not exist, however, on-going clinical trials focus on assess-
ing both traditional treatments and emerging therapies11. In brief, benefit of immunosuppressive treatment in 
standard care is being evaluated in the TESTING13 clinical trial. Spurred by increasing evidence of excessive 
immunoproteasomal activity in IgAN, the “BORTEZOMIB IN IgAN” clinical trial is investigating the benefits 
of proteasome inhibition. Owing to a better understanding of the role of mucosal immunity, B-cell activation 
and mesangial cell activation due to an exaggerated immune response in IgAN became the target of new promis-
ing therapies, investigated in phase II/III clinical trials14. Targeting mucosal B-cell induction (NEFIGAN trial)15 
as well as B-cell maturation and survival (BRIGHT-SC)16 has already shown promising preliminary results. 
Nonetheless, recently finalized STOP-IgAN trial17 assessing the added value of immunosuppression in IgAN 
treatment reported no additional benefit to basic supportive care18. Along the same lines, B-cell depletion by 
rituximab (RITUXIMAB IN IgAN study) showed a lack of benefit in improving kidney function19. Given that the 
efficacy of novel therapies in immune-mediated kidney diseases, including IgAN, is in most part disappointing, 
there is a continuous demand for better treatment strategies and novel targets20.
Until now, several IgAN biomarkers have been identified and validated. Serum levels of circulating 
galactose-deficient IgA121, IgA1-containing circulating immune complexes22, 23 and IgG autoantibodies specific 
for Gd-IgA123 were found to be good diagnostic biomarkers for IgAN. Additionally, serum levels of complement 
proteins, such as C3, factor H and fragments of complement activation proteins were found reflective of dis-
ease severity or clinical presentation24. Some promising biomarker candidates were also found in urine of IgAN 
patients, such as mannose-binding lectin (MBL) predicting disease progression25 or podocalyxin associated with 
IgAN activity26. Moreover, urinary peptidomics approaches have been utilized to develop non-invasive diagnostic 
tools based on a panel of differentially expressed molecules, able to differentiate IgAN from patients with other 
glomerular diseases27. None of the aforementioned markers has been implemented in clinical settings until now, 
stressing the unmet need for novel biomarkers, able to successfully diagnose early stages of the disease28.
Public availability of experimental data from multiple studies sparked efforts towards data integration strate-
gies, aiming at a better understanding of complex biological systems and phenomena29. Information-rich –omics 
datasets may increase reliability and generalizability of results, and most importantly, enable generation of novel 
hypotheses and insights30. System-level analyses have gained popularity, as reflected by reported studies suc-
cessfully utilizing data integration strategies31–33. Several different approaches and integration tools have been 
proposed for meta-analysis of data, however, translation of accumulated data into a meaningful biological context 
remains a challenge34. Collectively, systems biology-driven modelling pipelines are still under development and a 
standard, comprehensive workflow has not been established35.
In this study, we hypothesized that through meta-analysis of consolidated data from -omics studies on IgAN, 
novel biological traits relevant to the disease might be identified. Therefore, we developed a step-wise approach 
involving integration and pathway analysis of urine proteomics datasets, cross-validation of predictions through 
transcriptomics and tissue expression databases, shortlisting of candidates through further literature mining and 
experimental verification of selected targets by immunohistochemistry.
Results
Pathway analysis and functional candidates selection. The overall workflow of the analysis is 
depicted in Fig. 1. Database search using the database peptiCKDdb36 for IgAN-related datasets yielded two man-
uscripts focusing on peptidomics analyses (sample types: urine (1), blood (1)) and 10 manuscripts focusing on 
proteomic analyses using urine (9), blood (1), kidney (1) as sample material. Complementary literature search 
provided a limited number of additional manuscripts: we identified no additional peptidomics publications, one 
manuscript describing proteomics (not accessible), one urinary metabolomics and five on transcriptomics anal-
ysis (profiling of leukocytes (1), blood (2) and kidney (2)). Studies of the urine proteome (9 relevant manuscripts 
listed in Table 1) were the most prominent, hence analysis focused on these datasets. Data corresponding to 
differentially expressed proteins between patients suffering from IgAN and healthy controls, as reported by the 
authors (with fold change values and/or regulation reported; description of the statistical approach used in each 
case is provided in Supplementary Table S1), were integrated resulting in a list of 236 non-redundant proteins 
(Supplementary Table S1). Four proteins, collagen alpha-1(VI) chain, cystatin-C, dipeptidyl peptidase 4 and uro-
modulin were removed from the analysis due to conflicting regulation trends in different studies. Therefore, the 
final analysis input consisted of 232 proteins (167 downregulated, 65 upregulated) (Supplementary Table S2).
Pathway analysis was performed via two approaches, using the full urinary proteomics dataset (Approach 
1; Supplementary Table S2) and excluding bona fide plasma proteins (Approach 2; Supplementary Table S3), 
as these may reflect the failing glomerular filtration barrier, hence be an effect rather than the cause of the dis-
ease. Pathway enrichment of the full protein dataset yielded a list of 28 pathways (p-value < 0.05, Supplementary 
Table S4, Approach 1). Based on further critical evaluation, 13 pathways most likely irrelevant to IgAN) were not 
considered for further investigation. These included budding and maturation of HIV virion, visual phototrans-
duction and glycolysis; marked in grey in the Supplementary Table S4. Fifteen pathways remained as potentially 
relevant to the studied pathology including platelet activation, signalling and aggregation, membrane trafficking, 
binding and uptake of ligands by scavenger receptors, metabolism of angiotensinogen to angiotensin peptides and 
complement cascades (Supplementary Table S4).
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In comparison, after exclusion of a total of 42 plasma proteins from the analysis input the remaining 190 
proteins (152 downregulated, 38 upregulated, Supplementary Table S3) yielded 19 significant pathways 
(p-value < 0.05, Supplementary Table S5, Approach 2). After removing six irrelevant pathways (e.g. budding 
and maturation of HIV virion, glucose metabolism) 13 entries remained. There was a substantial overlap (40%) 
between the predicted pathways in the two approaches (including/excluding plasma proteins). Specifically, path-
ways related to platelet activation, signalling and aggregation, membrane trafficking, and metabolism of angio-
tensinogen to angiotensins appeared significant in both analyses. Nevertheless, some differences could also be 
observed - after exclusion of plasma proteins, new pathways potentially related to tissue-level events i.e. collagen 
formation, collagen biosynthesis and modifying enzymes, integrin cell surface interactions and EPH-ephrin sig-
nalling, were predicted as significantly deregulated in disease.
Taking into account both analytical approaches, 20 molecular pathways were predicted to be de-regulated 
in IgAN (Table 2). These pathways involved 70 proteins from the input dataset and additional 657 proteins par-
ticipating in these pathways. The latter were further analysed for their relevance to IgAN through a step-wise 
approach (summarized in Fig. 2 and described in detail below). Of note, pathway analysis of the individual pro-
teomics datasets gave results for 5 out of 9 sets (due to the low number of protein identifications reported in the 
remaining 4 datasets). Moreover, comparison of the pathways yielded from the integrated and single-set analysis 
showed that several significant pathways do not appear in each individual analysis (e.g. platelet activation, sig-
nalling and aggregation) or appear only upon integration (e.g. complement cascade) (Supplementary Table S9).
Nephroseq concept association analysis. Nephroseq association analysis was performed to identify 
common molecular features between the predicted 657 pathway building proteins and a collection of gene expres-
sion signatures related to IgAN i.e. Nephroseq “concepts”. A total of five IgAN-derived concepts were identified 
in the analysis (respective demographics and clinical information are summarized in Supplementary Table S6). 
Jointly, 223 IgAN-associated transcripts from Nephroseq were found overlapping with the 657 proteins from the 
input data (Supplementary Table S7). Those were subjected to further steps of assessment.
Tissue expression, PPIs, pathway count. Following the concept analysis in Nephroseq, the 223 short-
listed proteins were further examined using the Human Protein Atlas database for their expression in healthy 
kidney tissue. A subset of 153 proteins was reported to be expressed in kidney tissue. These were shortlisted based 
on the number of corresponding pathways as well as their potentially central role in these pathways, as reflected 
by number of their protein-protein interactions. Based on the latter analysis, a subset of 118 proteins forming 
more than one protein-protein interaction (STRING database) and/or being involved in more than one identified 
Figure 1. Schematic representation of the steps followed in the project. Initially, literature and database mining 
was performed to identify relevant datasets from IgAN human –omics experiments. Datasets were extracted 
from selected resources and pre-processed forming the input protein set subjected to pathway and interactome 
analysis. Investigation of pathways and multi-step shortlisting of predicted proteins supported by functional 
protein evaluation and literature mining yielded a list of disease-relevant targets, further validated in the kidney 
tissue via immunohistochemistry (IHC).
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pathway were selected for further functional assessment. The individual proteins with corresponding assessment 
are presented in Supplementary Table S7.
Assessment of function. The 118 proteins remaining after the aforementioned shortlisting steps were 
screened for their potential function in IgAN-related processes, namely function in immunity/autoimmunity, 
blood pressure regulation, vascular injury, oxidative stress and ECM remodelling. An initial screening was per-
formed by using UniProt and Gene Ontology databases, which highlighted 68 proteins of potentially higher 
relevance (Supplementary Table S8). The majority of shortlisted molecules (35%) originated from the statistically 
most significant pathway, platelet activation, signalling and aggregation pathway followed by EPH-ephrin signal-
ling (20%), vesicle mediated transport (13%), collagen formation (10%), integrin cell surface interactions (8%) 
and binding and uptake of ligands by scavenger receptors (8%) pathways (Fig. 3).
Consequently, literature databases were examined to place these findings in the context of existing IgAN liter-
ature and reveal novel findings. Individual assessment of shortlisted proteins resulted in a list of the 20 most sig-
nificant proteins predicted in the analysis, summarized in Table 3. Several proteins were previously described in 
the context of different renal diseases or relevant animal models as indicated in the table, including six molecules 
reported to be differentially expressed in the kidney tissue of patients suffering from IgAN, namely ACTN137, 
ACTN438, GAS639, PRR40, SPARC41 and MMP-242, supporting the validity of our approach.
To further investigate the reliability of our method, three proteins predicted to be functionally relevant in 
IgAN were selected for assessment of their expression in the kidney tissue via immunohistochemistry (IHC). 
Moreover, selection of those targets was guided by their novelty in the context of IgAN and availability of specific 
antibodies. Based on the bioinformatics analysis, we hypothesized that these proteins, adenylyl cyclase-associated 
protein 1 (CAP1), SHC-transforming protein 1 (SHC1) and prolylcarboxypeptidase (PRCP), are likely upregu-
lated in the kidney tissue of IgAN patients compared to healthy controls.
Validation of selected targets. Immunohistochemistry staining for validation targets, CAP1, SHC1 and 
PRCP, was performed on eight IgAN, three other glomerular diseases and one healthy control slides of kidney 
tissue. No staining was observed in case of negative controls, confirming the specificity of the IHC analysis. 
Clinical information, intensity levels (individual IHC scores) and respective images can be found in Table 4, 
Supplementary Table S10 and Supplementary Fig. S1 and S2, respectively. CAP1 showed negative/below limit of 
detection (−) staining in the normal kidney, negative (−) to strong (+++) staining in other glomerular diseases 
and weak (+) to strong (+++) staining in tubules and glomeruli with noticeable staining in inflammatory cells 
in the IgAN group. SHC1 and PRCP presented weak (+) staining in control kidney tissue and weak (+) to strong 
(+++) staining in the samples of other glomerular diseases and in the IgAN group. Overall, staining observed 
in the IgAN samples was stronger and more pronounced in comparison to control subjects, however there was 
no marked difference in the staining intensity in other glomerular diseases group. Therefore, the IHC results 
confirmed that the three selected proteins appear over-expressed in IgAN vs. healthy controls, but neither CAP1, 
SHC1 nor PRCP appear significantly upregulated in the kidney tissue of IgAN patients compared to patients with 
other glomerular diseases. These observations require further investigation in a larger number of samples per 
CKD aetiology.
Authors Title Proteomics method Dataset size Origin of proteins
Cohort 
(cases+control)
Park M.R. et al.80 Establishment of a 2-D human urinary proteomic map in IgA nephropathy. MALDI-TOF MS 59 proteins Soluble fraction 25
Rocchetti M.T. et al.81
Urine protein profile of IgA nephropathy 
patients may predict the response to ACE-
inhibitor therapy.
nano-HPLC-ESI-MS/MS 8 proteins Soluble fraction 38
Moon P.G. et al.82
Proteomic analysis of urinary exosomes 
from patients of early IgA nephropathy and 
thin basement membrane nephropathy.
LC-MS/MS 124 proteins Urinary exosomes 12
Graterol F. et al.83
Poor histological lesions in IgA 
nephropathy may be reflected in blood and 
urine peptide profiling.
MALDI-TOF MS 3 proteins Soluble fraction 33
Samavat S. et al.84 Diagnostic urinary proteome profile for immunoglobulin a nephropathy. nLC-MS/MS 46 proteins Soluble fraction 21
Rocchetti M.T. et al.85
Association of urinary laminin G-like 3 
and free K light chains with disease activity 
and histological injury in IgA nephropathy.
MALDI-TOF-MS/MS 2 proteins Soluble fraction 89
Yokota H. et al.86 Absence of increased alpha1-microglobulin in IgA nephropathy proteinuria. LC-MS/MS 10 proteins Soluble fraction 27
Surin B. et al.87 LG3 fragment of endorepellin is a possible biomarker of severity in IgA nephropathy. MALDI-TOF/TOF-MS 4 proteins Soluble fraction 73
Mucha K. et al.88
Complement components, proteolysis-
related, and cell communication-related 
proteins detected in urine proteomics are 
associated with IgA nephropathy.
IEF/LC-MS/MS 18 proteins Soluble fraction 60
Table 1. Characteristics of the urinary proteomics datasets used for the analysis. Proteomics method – mass 
spectrometry-based method applied in the study; Dataset size – differentially expressed proteins reported in the 
publication; Cohort – Total number of cases and controls).
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Discussion
Over the last decades, significant progress was achieved in understanding the pathology of IgAN, however, the 
critical molecular aspects of the disease remain unexplored43. Consequently, current treatment options for IgAN 
are lacking effectiveness and specificity14. In the era of high-throughput omics technologies, integration of heter-
ogeneous data holds the promise of providing new insights, through comprehensive reconstruction and predic-
tion of affected biological processes44. Adopting this approach, we integrated urine proteomics datasets mined 
from the literature, aiming at revealing connections between urinary proteome changes and kidney tissue events, 
and eventually, discovering novel proteins potentially involved in IgAN pathogenesis. The developed workflow 
involved extensive data analysis including pathway enrichment followed by a step-wise prioritization of predicted 
proteins. Taking into account information from high-quality information resources: Nephroseq database for 
transcriptomics data45, Human Protein Atlas for tissue expression data46, STRING database for protein-protein 
interactions47, as well as existing knowledge on molecular pathogenesis of IgAN, we obtained a list of candidates 
meriting further experimental validation and consideration as therapeutic targets. Experimental investigation 
of three of these shortlisted predicted targets, having IgAN-associated profile and functional relevance, verified 
their differential expression in the kidney tissue of IgAN patients compared to healthy control samples, further 
supporting the validity of our approach.
A substantial part of shortlisted proteins obtained from our prediction is involved in pathways related to 
processes of platelet activation, signalling and aggregation, thus, were pinpointed as potentially important factors 
of IgAN pathology. Notably, antiplatelet and anticoagulant agents, such as warfarin or statins, have been used for 
IgAN treatment in Asian countries and evaluated in several controlled studies, but due to poor study design and 
lack of standardization, definitive conclusions on their efficacy could not be drawn48, 49. Platelets are essential for 
haemostasis and are first responders in vascular injury and endothelial disruption. They are also inflammatory 
effectors with activities in acute inflammation, but also adaptive immunity and tissue remodelling50–53. Platelet 
# Pathway #genes coverage % p-value Genes up-regulated Genes down-regulated
1 Platelet activation, signalling and aggregation 23 10.45 2.55E-09 A2M, ALB, APOA1, F2, PSAP, SERPINA1, SERPINF2, TF
CFL1, EGF, FN1, GNA11, GNAI1, GNAI2, 
GNB1, GNB2, IGF2, KNG1, MAPK3, 
PFN1, PIK3R3, RAP1A, SERPING1
2 Platelet degranulation 14 17.72 2.04E-08 A2M, ALB, APOA1, PSAP, SERPINA1, SERPINF2, TF
CFL1, EGF, FN1, IGF2, KNG1, PFN1, 
SERPING1
3 Response to elevated platelet cytosolic Ca2+ 14 16.67 4.78E-08 A2M, ALB, APOA1, PSAP, SERPINA1, SERPINF2, TF
CFL1, EGF, FN1, IGF2, KNG1, PFN1, 
SERPING1
4 Scavenging of heme from plasma 6 50.00 3.00E-06 ALB, APOA1, HBA2, HBB, HP AMBP
5 Vesicle-mediated transport 19 7.95 1.31E-05 ALB, APOA1, CLTCL1, HBA2, HBB, HP
AMBP, CHMP4B, CHMP5, MYH8, 
RAB10, RAB14, RAB5C, TSG101, VPS37B, 
VPS4B, VTA1, YWHAG, YWHAQ
6 Intrinsic Pathway of Fibrin Clot Formation 6 27.27 2.05E-04 A2M, F2, SERPINC1 KNG1, SERPINA5, SERPING1
7 Endosomal Sorting Complex Required For Transport (ESCRT) 6 20.69 1.17E-03 —
CHMP4B, CHMP5, TSG101, VPS37B, 
VPS4B, VTA1
8 Formation of Fibrin Clot (Clotting Cascade) 6 15.38 6.81E-03 A2M, F2, SERPINC1 KNG1, SERPINA5, SERPING1
9 Binding and Uptake of Ligands by Scavenger Receptors 6 15.00 7.88E-03 ALB, APOA1, HBA2, HBB, HP AMBP
10 Membrane Trafficking 13 6.47 1.06E-02 CLTCL1
CHMP4B, CHMP5, MYH8, RAB10, 
RAB14, RAB5C, TSG101, VPS37B, VPS4B, 
VTA1, YWHAG, YWHAQ
11 Metabolism of Angiotensinogen to Angiotensins 4 25.00 1.47E-02 — ACE, ANPEP, ENPEP, MME
12 ADP signalling through P2Y purinoceptor 12 4 18.18 2.25E-02 — GNAI1, GNAI2, GNB1, GNB2
13 Signal amplification 5 15.63 2.45E-02 — GNA11, GNAI1, GNAI2, GNB1, GNB2
14 Thrombin signalling through proteinase activated receptors (PARs) 5 15.63 2.45E-02 F2 GNA11, GNB1, GNB2, MAPK3
15 Collagen formation 7 8.14 2.75E-02
COL11A1, COL11A2, 
COL15A1, COL17A1, 
COL22A1, COL4A4
CTSB
16 Collagen biosynthesis and modifying enzymes 6 9.38 3.31E-02
COL11A1, COL11A2, 
COL15A1, COL17A1, 
COL22A1, COL4A4
17 Integrin cell surface interactions 6 9.09 3.91E-02 COL4A4 AGRN, CD44, CDH1, FN1, HSPG2
18 EPH-Ephrin signalling 7 7.53 4.42E-02 ACTB, CLTCL1 ACTG1, ARHGEF7, CFL1, MYH9, SDCBP
19
Regulation of Insulin-like Growth Factor 
(IGF) transport and uptake by Insulin-like 
Growth Factor Binding Proteins (IGFBPs)
4 19.05 4.49E-02 F2 IGF2, IGFALS, KLK1
20 Complement cascade 5 13.51 4.90E-02 C3, C4A C7, CD55, MASP2
Table 2. Significant pathways yielded from the analysis of full urine proteomics dataset (Approach-1) and after 
exclusion of plasma proteins (Approach-2). Pathways specific for Approach-1 are bolded and pathways specific 
for Approach-2 are underlined. The original lists of pathways obtained from both analyses can be found in the 
supplementary material.
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activation is common in chronic kidney disease (CKD)54, acute kidney injury55, and nephrotic syndrome alike56. 
Moreover, platelet degranulation is observed along with atherogenesis in diabetes mellitus, where correlation 
was found between increased platelet degranulation markers (CD63 and CD40L) and atherosclerosis progres-
sion57. Proteins found in platelet-related pathways included mediators of inflammatory response such as adeny-
lyl cyclase-associated protein 1 (CAP1), guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) and 
tyrosine-protein phosphatase non-receptor type 1 (PTPN1), as well as alpha-actinin-1 (ACTN1), alpha-actinin-4 
(ACTN4) and growth arrest-specific protein 6 (GAS6), already reported to be differentially expressed in the kid-
ney tissue of IgAN patients. We selected CAP1, a functional receptor of resistin, as a target for validation in the 
kidney tissue of IgAN patients. Notably, elevated resistin levels in chronic kidney disease have been reported in 
different studies and are associated with decreased GFR and inflammation58, 59. CAP1 is essential for mediation of 
inflammatory action of monocytes and thus, has been suggested as potential target for treatment of inflammatory 
diseases60. Moreover, induced infiltration of monocytes has been extensively reported in IgAN patients61, 62. Given 
this evidence and the fact that CAP1 has not been studied in the context of kidney disease, it appears to be an 
excellent candidate molecule for further investigation. The IHC staining confirmed its differential expression in 
IgAN tissue, in tubules, glomeruli and in inflammatory cells, underlining its potential relevance.
Scavenging of heme from plasma was the second most prominent pathway, identified as upregulated in IgAN. 
It is related to increased release of haemoglobin (Hb) and heme63. Extracellular haemoglobin triggers acute and 
chronic vascular disease, inflammation, thrombosis, and renal impairment, pathophysiological conditions that 
are associated with adverse clinical outcomes. Furthermore, oxidative stress, that can be induced by haemoglo-
bin and heme, causes severe damage to tissues - kidney in particular64. Along these lines, oxidative stress has 
Figure 2. Classification tree used for selection of validation candidates based on the results from Cytoscape 
pathway analysis. The integrated dataset constructed by combining data from 9 urine proteomics manuscripts 
was subjected to pathway analysis in Cytoscape (ClueGO plug-in). 20 pathways were found significant. 
Predicted molecules involved in the pathways were evaluated in order to identify novel molecules potentially 
involved in IgAN pathology. The process of multi-step assessment included transcriptomics association 
analysis (Nephroseq database) and investigation of tissue expression data (Human Protein Atlas), followed by 
application of protein-protein interactions (STRING database) and pathway occurrence thresholds, as well as 
functional evaluation (UniProt, GeneOntology). 68 shortlisted molecules were subjected to detailed literature 
mining in order to select the most disease-relevant findings.
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been recognized as a mediator of inflammation in IgAN65, 66. Moreover, increased levels of plasma Hb and heme 
may induce platelet activation and thrombosis contributing to vascular inflammation and consequently vascular 
obstruction67. Following our analysis, shortlisted proteins of interest involved in heme scavenging and oxidative 
stress response included stabilin-1 (STAB1) and SHC-transforming protein 1 (SHC1). STAB1, one of the markers 
of monocytes, has been found to be associated with cardiovascular diseases68. Further studies highlight its role in 
maintenance of tissue homeostasis and possible therapeutic utility in chronic inflammation69. SHC1 is involved 
in modulating the cellular response to oxidative stress. Drug induced regulation of SHC1 levels may offer a novel 
therapeutic approach for kidney disease treatment by reducing oxidative stress70, a hypothesis which prompted, 
as a first step, the investigation of SHC1 expression in the IgAN kidney tissue. In support of this hypothesis, a 
recent study on SHC1 revealed that its isoform p66Shc is a potential novel biomarker of tubular oxidative injury 
in patients with diabetic nephropathy71. Specifically, p66Shc levels were increased in DN patients vs. healthy con-
trols in both, peripheral blood monocytes (PBMs) and renal tissues and positively correlated with the duration 
of diabetes, levels of triglycerides, HbA1C, LDL-C, blood glucose, tubular interstitial damage and renal oxidative 
stress. In a mouse model, p66Shc acted as a negative regulator of autoimmune glomerulopathy: p66Shc knockout 
mice developed a lupus-like autoimmune disease characterized by autoantibody production and immune com-
plex deposition in kidney, resulting in autoimmune glomerulonephritis72. These results collectively suggest that 
overexpression of SHC1, as predicted through our integrative approach and observed following the IHC valida-
tion, may be a protective mechanism, meriting further investigation.
Besides the two aforementioned, the metabolism of angiotensinogen to angiotensins was identified in the 
significantly altered pathways in the analysis. Importantly, polymorphisms in the renin–angiotensin system 
(RAS) genes have already linked the hypertension aspect of renal diseases to IgAN73. Angiotensin II (Ang II) 
is a well-known cause of glomerular hypertension and hyperfiltration. Moreover, it was reported overexpressed 
in biopsies of IgAN patients suggesting its stronger impact on IgAN than other glomerular diseases74. Similarly, 
(Pro)renin receptor (PRR) was identified overexpressed in IgAN biopsy samples40. PRR was predominantly local-
ized in the cytoplasm of renal tubular cells and its levels correlated with urinary total protein levels, possibly 
reflecting disease severity40. The selected validation candidate - prolylcarboxypeptidase (PRCP), regulates blood 
pressure and electrolyte balance, cleaving Ang II or Ang III75. Along these lines, PRCP deficiency was reported to 
impair Ang II degradation and thus, its increase may be associated with hypertension and glomerular lesions76, 77. 
PRCP has also been shown to be an activator of the cell matrix-associated pre-kallikrein and molecular events 
upstream of the fibrinolytic system78. In addition, elevated plasma PRCP levels were reported in diabetic and 
obese patients and significantly increased expression of PRCP during consecutive stages of renal disease develop-
ment associated with inflammation79. In our study, tissue staining showed strong expression of PRCP in kidneys 
from IgAN patients, with evident, very strong staining in granules. Collectively, these results suggest that PRCP 
has pleiotropic effects, acting in a context-specific manner, hence further investigation of its role in IgAN appears 
reasonable.
In summary, although quite simplistic, our analysis captures important aspects of IgAN pathophysiology. We 
demonstrate the utility of urinary proteomics for biological investigations, and in addition, that data integra-
tion provides increased coverage and more insights to processes altered in IgAN, which cannot be predicted by 
single-set analysis. Several major pathways (and thus, predicted targets), which constitute the backbone of our 
analysis, were not detected through analysis of each dataset individually or would not appear if the integration 
step was not applied. Through the application of this systems-level approach to –omics data analysis, we pre-
dicted and further experimentally validated key molecules, such as CAP1, SHC1 and PRCP, that might play a 
significant role in IgAN pathogenesis. Moreover, we highlight other protein targets which could be of interest for 
further investigation in the context of IgAN.Through the application of this systems-level approach to –omics 
Figure 3. Distribution of 68 shortlisted proteins among pathways yielded from the pathway enrichment 
analysis.
www.nature.com/scientificreports/
8SCIeNTIFIC RepoRts | 7: 9091  | DOI:10.1038/s41598-017-09393-w
data analysis, we predicted and further experimentally validated key molecules, such as CAP1, SHC1 and PRCP, 
that might play a significant role in IgAN pathogenesis. Moreover, we highlight other protein targets which could 
be of interest for further investigation in the context of IgAN.
Despite being comprehensive, our analysis has several limitations. First of all, we restricted input to urine 
proteomics datasets that form the majority of published studies for the specific disease. Additionally, given that 
the extracted datasets were based on comparisons of IgAN vs. healthy controls, the predicted targets might not 
be specific to IgAN, but reflect general kidney disease. This observation is in part supported by the occasional 
marked expression of the investigated proteins in kidney tissue with other glomerular diseases (Supplementary 
Figure 2) and certainly requires further investigation in a larger sample cohort. Furthermore, cofounding factors 
(for example differences in cohort sizes, patients’ ethnicity, age, sex or comorbidities) are not taken into account, 
which collectively may affect the analysis output. An additional shortcoming of our study is using transcriptom-
ics datasets and the number of known protein-protein interactions for prioritization of our predictions, through 
Gene Protein name Function (UniProt) Literature
Platelet activation, signalling and aggregation
ACTN1 Alpha-actinin-1 actin anchoring, bundling protein Validated in IgAN kidney tissue37
ACTN4 Alpha-actinin-4 actin anchoring, bundling protein Validated in IgAN kidney tissue38
CAP1 Adenylyl cyclase-associated protein 1 complex developmental and morphological processes, actin cytoskeleton organization
functional receptor for human resistin, 
inflammatory action of monocytes60
GAS6 Growth arrest-specific protein 6 ligand, negative regulation of renal albumin absorption, cell growth and survival, implicated in hypertension Validated in IgAN kidney tissue
39
GNAQ Guanine Guanine nucleotide-binding protein G(q) subunit alpha
modulators or transducers in various transmembrane 
signalling systems, modulation of B-cell selection and survival
maintenance of B-cell tolerance, autoimmunity 
repression89
PTPN1 Tyrosine-protein phosphatase non-receptor type 1
Tyrosine-protein phosphatase, regulator of endoplasmic 
reticulum unfolded protein response
control of B cell activation and the maintenance 
of immunological tolerance, induction of 
migratory podocyte response90–92
SHC1 SHC-transforming protein 1 Signalling adapter, couples activated growth factor receptors to signalling pathways
pivotal regulator of oxidative stress (p66Shc 
isoform), putative marker of tubular oxidative 
injury in DN71
WDR1 WD repeat-containing protein 1 disassembly of actin filaments platelet-related complications in CKD93
EPH-Ephrin signalling
ADAM10 Disintegrin and metalloproteinase domain-containing protein 10 protease
expressed in human podocytes, may be involved 
in the development of glomerular kidney 
diseases through Notch signalling pathway94
EFNA4 Ephrin-A4 ligand for Eph receptors, interaction between activated B-lymphocytes and dendritic cells in tonsils signalling in injury and inflammation
95
Collagen formation
BMP1 Bone morphogenetic protein 1 protease involved in renal fibrosis96
CTSS Cathepsin S thiol protease promotes vascular inflammation and calcification97, 98
PLOD2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Collagen crosslinking enzyme —
Integrin cell surface interactions
F11R Junctional adhesion molecule A epithelial tight junction formation, regulation of monocyte transmigration
possible pathogenic role in arterial 
hypertension99
JAM3 Junctional adhesion molecule C cell-cell adhesion, mediator of angiogenesis, regulation of transepithelial migration of polymorphonuclear neutrophils
inflammation and vascular biology, mediation 
of leukocyte infiltration in response to ischemia 
reperfusion injury100
Binding and Uptake of Ligands by Scavenger Receptors
SPARC SPARC regulation of cell growth through interactions with the extracellular matrix and cytokines Validated in IgAN kidney tissue
41
STAB1 Stabilin-1 scavenger receptor for acetylated low density lipoprotein Maintenance of tissue homeostasis68, 69
Metabolism of Angiotensinogen to Angiotensins
ATP6AP2/PRR Renin receptor renin and prorenin cellular receptor, may play a role in the renin-angiotensin system (RAS) Validated in IgAN kidney tissue
40
Formation of Fibrin Clot (Clotting Cascade)
PRCP Prolylcarboxypeptidase peptidase
activity associated with cardiovascular risk 
factors, such as atherosclerosis, inflammation, 
and diabetes75
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MMP2 Matrix metalloproteinase-2
protease, remodelling of the vasculature, angiogenesis, tissue 
repair, tumour invasion, inflammation, and atherosclerotic 
plaque rupture
Validated in IgAN kidney tissue42
Table 3. Summary of the most significant findings predicted following application of a series of steps involving 
pathway analysis, as well as cross-checking through transcriptomics (Nephroseq concept association analysis), 
protein expression (Human Protein Atlas) and protein-protein interactions (STRING) databases and literature 
mining.
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which we shift the emphasis towards known molecular features. However, this is a principal shortcoming of 
knowledge-based bioinformatics approaches. On a positive note, the obtained enriched pathways reflect better 
the disease heterogeneity at the level of individual molecules, but also the “common denominator” of the IgAN 
molecular pathology. Expansion of the analysis to include additional datasets, investigating on this occasion 
overlaps of IgAN predictions with other autoimmune diseases, in parallel to a more in-depth investigation of the 
biological relevance and therapeutic potential of the shortlisted targets are warranted.
Methods
Preparation of an integrated –omics dataset for the analysis. Proteomics datasets were extracted 
from the peptide/protein-centric database PeptiCKDdb (www.peptiCKDdb.com)36. In brief, peptiCKDdb is a 
resource of manually curated human proteomics and peptidomics datasets extracted from published scientific 
studies relative to chronic kidney disease (CKD). The database was searched for datasets extracted from studies 
related to IgAN, with patients not suffering from IgAN used as controls.
Moreover, PubMed was screened to identify high throughput -omics studies not included in the data-
base. The search (conducted September 2016) included the following keywords: “IgAN AND proteomics” 
(16 results), “IgAN AND peptidomics” (0 results), “IgAN AND transcriptomics” (1 results), “IgAN AND 
metabolomics” (1 results), “IgAN AND profiling” (14 results) and was limited to human case-control stud-
ies. Obtained references were searched for further relevant datasets of differentially expressed molecules. 
Datasets consisting of a list of molecules showing differential expression (based on p-value < 0.05 and/or 
reported criteria) with assigned regulation trend (or fold change/ratio) in IgAN vs. healthy control group 
were extracted and integrated into a “final” dataset, further used as an input for the pathway enrichment 
analysis. Molecules appearing in multiple datasets, but showing inconsistent regulation trend were not 
included in the analysis.
Pathway enrichment analysis. Pathway enrichment analysis was performed in Cytoscape software (www.
cytoscape.org), using ClueGO plug-in for the network visualization. The urine proteomics dataset was introduced 
as a set of clusters of down- and up-regulated molecules, with the gene name being used as the feature iden-
tifier. ClueGO pathway source was set for Reactome pathway database (www.reactome.org). Only statistically 
significant pathways (p-value < 0.05; two-sided hypergeometric test, Fisher Exact corrected with Bonferroni) 
were retained. Default parameters were used for Advanced Term/Pathway selection options, Grouping options 
and CluePedia options. Pathway analysis was performed using two approaches, in order to identify all processes 
altered in the course of the disease. In the first approach, all extracted features were used as an input for the 
analysis. In the second approach, major plasma proteins were excluded from the analysis input, based on the 
hypothesis that their presence is a result of the disease e.g. the disrupted glomerular filtration barrier, rather than 
a causative event contributing to the development of the disease pathophysiology. To prove the added value of 
analysis of the integrated dataset vs. single dataset, additional pathway enrichment analysis was performed on 
each individual dataset and results were evaluated.
Multi-step finding assessment. Proteins involved in each significant pathway identified in the enrichment 
analysis, but not being a part of the input dataset, were subjected to multi-step assessment to identify novel (not 
yet detected in the existing proteomics studies) putative disease-related proteins. Steps followed in the process of 
shortlisting the predicted molecules are depicted in Fig. 2. Shortlisting was initially performed in an objective, 
semi-automated manner (Nephroseq concept association analysis with transcriptomics data, described below), 
followed by a more subjective, final evaluation of potential validation targets based on functional assessment 
through literature mining.
Group
Sample 
ID
Intensity of staining
CAP1 SHC1 PRCP
Cases
IgAN 305 +++ +++ ++
IgAN 313 +++ +++ ++
IgAN 315 +++ NA ++
IgAN 312 +++ +++ +++
IgAN 310 − +++ +++
IgAN 302 ++ + +++
IgAN 306 + +++ ++
IgAN 307 + ++ ++
Controls
glomerular disease 311 − ++ +
glomerular disease 309 +++ +++ +++
glomerular disease 303 + ++ +
kidney kidney − + +
Table 4. Assessment of IHC staining of the clinical samples for CAP1, SHC1 and PRCP. Intensity of staining 
in the tissue was graded as “negative/below limit of detection” (−), “weak” (+), “medium” (++) or “strong” 
(+++). The respective figures are provided in Supplementary Figures 1 and 2. NA – not available.
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Nephroseq concept association analysis. Concept association analysis is available from the Nephroseq database 
(www.nephroseq.org, version September 2016)45. Nephroseq concepts are groups of differentially expressed genes 
in specific diseases. They are derived from deposited datasets that involve comparison of at least two groups. Each 
concept contains top 1, 5, and 10 percent of the over- and under-expressed genes from the respective dataset. 
Concept association analysis allows for comparison of user gene/protein dataset to genes in Nephroseq-derived 
concepts, in order to identify overlapping molecular features. The list of proteins predicted in pathway analysis 
of the urine proteomics datasets was used as input in Nephroseq concept association analysis. Default analysis 
settings were applied: odds ratio threshold = 2, p-value threshold = 0.0001. Significant concepts (p-value < 0.05, 
having at least 3 overlapping genes with the input data) related to IgAN were retained. The respective demograph-
ics, pathology or tissue type are summarized in Supplementary Table S6. Molecules overlapping between the 
input proteomic dataset and Nephroseq concepts related to IgAN were selected for further evaluation.
Tissue expression, PPIs, occurrence in pathways. The molecules highlighted from the concept association analysis 
were investigated for expression in healthy kidney tissue through the Human Protein Atlas (www.proteinatlas.
org)46. Features with IHC evidence for kidney expression were retained for further investigation. Similarly, for 
each protein, the number of pertinent protein-protein interactions in the corresponding pathway was estimated 
(STRING database47; www.string-db.org; prediction methods: all, score: highest confidence (0.9)). Additionally, 
the frequency of occurrence of each molecule in the identified pathways was calculated. Of note, pathways sharing 
the same parent node (e.g. platelet activation, signalling and aggregation is the parent node for platelet degranula-
tion and signal amplification pathways) were combined and considered as one pathway. Molecules being involved 
in > 1 PPI and/or present in > 1 pathway were subjected to further functional assessment.
Functional assessment. Initial functional evaluation was performed using UniProt (www.uniprot.org) and 
GeneOntology (www.geneontology.org) databases, with focus on protein function and relevant biological 
processes. Given the pathological background of IgAN, involvement in immunity/autoimmunity, blood pres-
sure regulation, vascular injury, oxidative stress and ECM remodelling was considered for protein shortlisting. 
Subsequently, shortlisted molecules were searched in the literature resources (PubMed/ Web of Science) to fur-
ther shortlist proteins meriting further experimental verification.
Experimental validation. Human kidney biopsy samples. Sections of paraffin-embedded human kid-
ney tissue were obtained from biopsy-proven IgAN patients (n = 8) and patients with other glomerular diseases 
(tubulointerstitial nephritis, focal segmental glomerulosclerosis and mesangial proliferative glomerulone-
phritis, n = 3). Normal kidney control tissue was obtained from the normal kidney region after renal tumour 
nephrectomy. Clinical characteristics of patients are included in the Supplementary Table S10. Sample collec-
tion was performed in accordance to local ethics requirements and the study was approved by the local ethics 
committees of Wroclaw Medical University, Wroclaw, Poland (No. KB-88/2013), Timisoara County Emergency 
Clinical Hospital, Timisoara, Romania (No. 84; 8/08/2015) and University of Glasgow. The “CKD-BIO Study” 
was approved by the institutional review board of the Ethic Subcommittee for Medicine, Pharmacy, Veterinary 
and Stomatology of the Macedonian Academy of science and Arts (12/02/2015). All individuals gave written 
informed consent. Institutional review board approval was obtained for procurement of kidney specimens at the 
University of Glasgow.
Immunohistochemistry. Immunostaining of paraffin-embedded kidney tissues was performed on 2.5-µm tissue 
sample sections using UltraVision Quanto Detection System (Thermo Scientific), following the manufacturer’s 
instructions. Primary antibodies included rabbit recombinant monoclonal anti-CAP1, rabbit recombinant mon-
oclonal anti-SHC and rabbit polyclonal anti-PRCP antibodies provided by Abcam (ab155079, ab33770, ab171846 
respectively). Incubation with primary antibody was performed with the following dilutions: CAP1 (1:100), SHC1 
(1:400), PRCP (1:20). After counterstaining with haematoxylin, slides were dehydrated and mounted with DPX 
mounting medium. Slides were digitized using Hamamatsu NDP slide scanner and viewed on Slidepath Digital 
Image Hub (Leica Microsystems). Intensity of staining in the tissue was graded in different kidney compartments 
(tubules, endothelial cells, glomeruli) as “negative” (−), “weak” (+), “medium” (++) or “strong” (+++). For 
each staining target, negative control was performed through omission of primary antibody.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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